Piramal Enterprises Limited
NSE: PEL BSE: PEL
NSE
1,173.70
49.50 (4.40%)
Prev Close
1124.2
Open Price
1124.2
Volume
1,087,297
Today Low / High
1121.1 / 1178.3
52 WK Low / High
804.8 / 1275
Range
1,115 - 1,232
BSE
1,174.25
48.50 (4.31%)
Prev Close
1125.75
Open Price
1125.75
Volume
51,913
Today Low / High
1122.6 / 1177.8
52 WK Low / High
804 / 1275.4
Range
1,116 - 1,233
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1173.7 (target range: 1,115 - 1,232), reflecting a change of 49.5 (4.40313%). On the BSE, it is listed at 1174.25 (target range: 1,116 - 1,233), showing a change of 48.5 (4.30824%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
06 Jun
1,124.20
4.40%
05 Jun
1,129.40
-0.46%
04 Jun
1,147.40
-1.39%
03 Jun
1,125.00
0.80%
02 Jun
1,108.20
1.65%
30 May
1,105.00
0.29%
29 May
1,090.95
0.67%
28 May
1,100.00
-1.27%
27 May
1,087.95
1.06%
26 May
1,101.00
-1.64%
23 May
1,091.00
0.89%
22 May
1,140.00
-4.32%
21 May
1,098.10
3.72%
20 May
1,120.00
-1.10%
19 May
1,105.00
1.51%
16 May
1,069.60
3.29%
15 May
1,076.00
-0.51%
14 May
1,075.00
-0.23%
13 May
1,063.90
1.12%
12 May
1,013.75
4.79%
09 May
984.85
2.75%
Piramal Enterprises Limited Graph
Piramal Enterprises Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Piramal Enterprises Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,173.70, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,174.25 | 1,185.99 | 1,067.39 - 1,304.59 |
| 1,197.74 | 958.19 - 1,437.28 | ||
| 1,209.48 | 846.63 - 1,572.32 | ||
| Bearish Scenario | 1,174.25 | 1,162.51 | 1,046.26 - 1,278.76 |
| 1,150.77 | 920.61 - 1,380.92 | ||
| 1,139.02 | 797.32 - 1,480.73 |
Overview of Piramal Enterprises Limited
ISIN
INE140A01024
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
617,272
Market Cap
266,051,968,600
Last Dividend
10
Official Website
IPO Date
1996-01-02
DCF Diff
-782.36
DCF
1,956
Financial Ratios Every Investor Needs
Stock Dividend of PEL
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-06-13 | June 13, 25 | 11 | 11 | 2025-06-13 | 2025-07-30 | |
| 2024-07-05 | July 05, 24 | 10 | 10 | 2024-07-05 | 2024-08-07 | |
| 2023-06-16 | June 16, 23 | 31 | 31 | 2023-06-16 | 2023-07-30 | |
| 2022-07-14 | July 14, 22 | 33 | 33 | 2022-07-15 | 2022-08-28 | |
| 2021-07-06 | July 06, 21 | 33 | 33 | 2021-07-07 | 2021-08-15 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 9,265.53 Cr | 2,900.25 Cr | 6,365.28 Cr | 0.6870 | 0.00 Cr | 689.80 Cr | 4,783.41 Cr | -1,683.53 Cr | -72.82 | -386.11 Cr | -0.1817 |
| 2023-03-31 | 8,031.79 Cr | 2,220.49 Cr | 5,811.30 Cr | 0.7235 | 0.00 Cr | 607.26 Cr | 3,794.49 Cr | 9,968.58 Cr | 603.52 | 8,684.95 Cr | 1.2411 |
| 2022-03-31 | 7,642.74 Cr | 1,901.88 Cr | 5,740.86 Cr | 0.7512 | 128.34 Cr | 307.93 Cr | 4,999.10 Cr | 1,923.11 Cr | 80.70 | 5,655.03 Cr | 0.2516 |
| 2021-03-31 | 12,770.76 Cr | 3,867.56 Cr | 8,903.20 Cr | 0.6972 | 79.31 Cr | 362.33 Cr | 6,928.52 Cr | 1,332.34 Cr | 56.19 | 8,105.18 Cr | 0.1043 |
| 2020-03-31 | 12,969.23 Cr | 3,278.53 Cr | 9,690.70 Cr | 0.7472 | 71.96 Cr | 308.60 Cr | 7,790.42 Cr | 24.03 Cr | -34.80 | 7,128.67 Cr | 0.0019 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 3,273.53 Cr | 82,605.00 Cr | 56,047.95 Cr | 26,557.0500 Cr | 53,585.93 Cr | 50,312.40 Cr | 0.00 Cr | 630.06 Cr | 0.00 Cr | 0.00 Cr | 10,333.76 Cr | 16,832.0100 Cr |
| 2023-03-31 | 3,729.00 Cr | 4,676,820.53 Cr | 4,645,761.45 Cr | 31,059.0800 Cr | 49,510.85 Cr | 45,781.85 Cr | 0.00 Cr | 556.45 Cr | -15,775.08 Cr | 140.43 Cr | 22,355.22 Cr | 1,192.3900 Cr |
| 2022-03-31 | 6,440.16 Cr | 99,872.91 Cr | 63,036.00 Cr | 35,489.1400 Cr | 55,702.96 Cr | 49,262.80 Cr | 1,533.01 Cr | 4,313.74 Cr | 5,208.31 Cr | 46.03 Cr | 17,529.27 Cr | 18,699.8800 Cr |
| 2021-03-31 | 5,719.01 Cr | 77,118.86 Cr | 41,979.90 Cr | 34,017.9600 Cr | 39,557.06 Cr | 33,838.05 Cr | 1,299.23 Cr | 3,327.10 Cr | 819.13 Cr | 35.49 Cr | 14,038.94 Cr | 13,347.2500 Cr |
| 2020-03-31 | 4,340.94 Cr | 74,908.58 Cr | 44,336.99 Cr | 30,571.5900 Cr | 42,238.20 Cr | 37,897.26 Cr | 1,061.17 Cr | 2,880.67 Cr | 867.77 Cr | 31.48 Cr | 12,606.18 Cr | 23,673.0000 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 26.4300 Cr | -1,871.6000 Cr | 1,389.7000 Cr | -1,243.2600 Cr | -455.4700 Cr | 3,273.5300 Cr | -1,269.6900 Cr | -1,683.5300 Cr | 4,230.8500 Cr | -739.8600 Cr | 0.0000 Cr |
| 2023-03-31 | 1,359.3400 Cr | -351.2400 Cr | -3,324.5300 Cr | 1,156.7400 Cr | -2,555.0600 Cr | 3,729.0000 Cr | -202.6000 Cr | -2,464.3400 Cr | -2,499.4500 Cr | -787.5900 Cr | -2,127.9800 Cr |
| 2022-03-31 | 8,749.5900 Cr | -2,226.1800 Cr | -6,987.9700 Cr | 7,791.1700 Cr | 699.9800 Cr | 6,281.6300 Cr | -958.4200 Cr | 2,024.6800 Cr | -6,095.9300 Cr | -797.5900 Cr | -253.1800 Cr |
| 2021-03-31 | 3,664.5400 Cr | -2,772.2500 Cr | 2,071.5800 Cr | 3,069.3600 Cr | 2,970.0700 Cr | 5,581.6500 Cr | -595.1800 Cr | 3,058.4800 Cr | -596.5300 Cr | -315.7500 Cr | -231.2400 Cr |
| 2020-03-31 | 7,516.3400 Cr | 7,468.6900 Cr | -13,018.5600 Cr | 7,045.6800 Cr | 1,988.3400 Cr | 2,611.5800 Cr | -470.6600 Cr | 811.1900 Cr | -14,827.6800 Cr | -667.9600 Cr | -304.4200 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 2,298.30 Cr | 438.47 Cr | 1,859.83 Cr | 0.8092 | 1,605.95 Cr | 38.56 Cr | 1.71 | 1,508.85 Cr | 0.0168 |
| 2024-09-30 | 2,182.30 Cr | 425.43 Cr | 1,756.87 Cr | 0.8051 | 1,466.91 Cr | 162.97 Cr | 7.23 | 1,550.63 Cr | 0.0747 |
| 2024-06-30 | 2,037.39 Cr | 388.04 Cr | 1,649.35 Cr | 0.8095 | 1,379.74 Cr | 181.48 Cr | 8.10 | 1,495.10 Cr | 0.0891 |
| 2024-03-31 | 3,477.41 Cr | 1,849.90 Cr | 1,627.51 Cr | 0.4680 | 994.48 Cr | 137.09 Cr | 6.10 | -1,085.57 Cr | 0.0394 |
| 2023-12-31 | 2,085.48 Cr | 370.89 Cr | 1,714.59 Cr | 0.8222 | 1,396.46 Cr | -2,377.59 Cr | -106.39 | -2,191.16 Cr | -1.1401 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 1,978.82 Cr | 1,342.27 Cr | 3,321.09 Cr | 0.00 Cr | 0.00 Cr | 65,973.23 Cr | 563.69 Cr | 86,756.17 Cr | 59,826.23 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -26,557.05 Cr |
| 2024-03-31 | 4,446.80 Cr | 1,173.27 Cr | 4,446.80 Cr | 66.46 Cr | 0.00 Cr | 62,305.87 Cr | 630.06 Cr | 82,605.00 Cr | 56,047.95 Cr |
| 2023-12-31 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 2,797.23 Cr | 1,118.95 Cr | 3,916.18 Cr | 0.00 Cr | 0.00 Cr | 57,376.38 Cr | 559.06 Cr | 81,645.11 Cr | 52,934.98 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 181.48 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 137.09 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | -2,377.59 Cr | 82.76 Cr | 0.00 Cr | 0.00 Cr | 82.76 Cr | 3,998.94 Cr | 3,916.18 Cr | 0.00 Cr | 82.76 Cr |
| 2023-09-30 | 48.19 Cr | 76.54 Cr | 0.00 Cr | 0.00 Cr | 76.54 Cr | 3,916.18 Cr | 3,839.64 Cr | 0.00 Cr | 76.54 Cr |
| 2023-06-30 | 508.78 Cr | 74.40 Cr | 0.00 Cr | 0.00 Cr | 74.40 Cr | 3,825.54 Cr | 3,751.14 Cr | 0.00 Cr | 74.40 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2019-12-30 | December 30, 19 | 128:125 |
| 2004-12-27 | December 27, 04 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,679.20 | ₹4,028,870,976,000.00 | ₹2,500,031.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,544.50 | ₹1,737,361,870,500.00 | ₹361,018.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,320.90 | ₹1,100,458,988,118.00 | ₹2,158,463.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,154.30 | ₹1,067,557,063,500.00 | ₹86,576.00 |
| Mankind Pharma Limited | MANKIND | ₹2,352.40 | ₹970,767,378,020.00 | ₹353,197.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹960.15 | ₹966,131,734,500.00 | ₹810,089.00 |
| Lupin Limited | LUPIN | ₹1,999.60 | ₹913,207,322,000.00 | ₹1,289,535.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,161.10 | ₹674,369,202,200.00 | ₹392,642.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,862.50 | ₹581,384,812,500.00 | ₹181,782.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,590.20 | ₹448,756,030,200.00 | ₹940,265.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,055.10 | ₹403,646,450,141.00 | ₹209,681.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,370.90 | ₹347,802,813,600.00 | ₹594,702.00 |
| Laurus Labs Limited | LAURUSLABS | ₹642.05 | ₹346,227,388,650.00 | ₹1,658,718.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,571.30 | ₹321,186,225,600.00 | ₹84,218.00 |
| Piramal Enterprises Limited | PEL | ₹1,173.70 | ₹266,051,968,600.00 | ₹1,087,297.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,702.30 | ₹265,322,180,300.00 | ₹62,791.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,790.00 | ₹244,750,000,000.00 | ₹123,199.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,505.40 | ₹244,595,886,600.00 | ₹803,276.00 |
| Eris Lifesciences Limited | ERIS | ₹1,638.30 | ₹223,111,885,500.00 | ₹55,563.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹987.60 | ₹194,125,618,800.00 | ₹40,498.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,140.00 | ₹181,580,340,000.00 | ₹116,733.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,030.00 | ₹167,173,597,000.00 | ₹539,376.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,093.30 | ₹159,115,291,610.00 | ₹64,315.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹858.30 | ₹153,730,113,000.00 | ₹354,578.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹529.95 | ₹128,536,192,800.00 | ₹485,798.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,560.50 | ₹92,300,963,700.00 | ₹8,096.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹914.45 | ₹89,424,888,505.00 | ₹310,698.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹909.25 | ₹82,409,528,235.00 | ₹242,116.00 |
| Strides Pharma Science Limited | STAR | ₹782.30 | ₹72,098,880,210.00 | ₹430,298.00 |
| FDC Limited | FDC | ₹429.20 | ₹69,878,052,000.00 | ₹308,089.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹165.55 | ₹53,724,617,100.00 | ₹2,347,837.00 |
| Innova Captab Limited | INNOVACAP | ₹889.10 | ₹50,878,685,263.00 | ₹72,505.00 |
| Suven Life Sciences Limited | SUVEN | ₹221.19 | ₹48,235,788,060.00 | ₹1,475,325.00 |
| Sequent Scientific Limited | SEQUENT | ₹187.85 | ₹47,019,230,700.00 | ₹442,806.00 |
| Hikal Limited | HIKAL | ₹372.35 | ₹45,911,127,350.00 | ₹154,610.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹462.15 | ₹42,180,430,500.00 | ₹112,178.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹592.90 | ₹41,743,598,820.00 | ₹18,878.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹368.10 | ₹36,912,331,800.00 | ₹50,918.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹718.15 | ₹36,423,921,665.00 | ₹149,821.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,141.70 | ₹35,421,576,300.00 | ₹12,390.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹64.12 | ₹35,134,810,480.00 | ₹2,840,731.00 |
| Alembic Limited | ALEMBICLTD | ₹112.07 | ₹28,777,558,628.00 | ₹591,652.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹88.74 | ₹26,047,585,980.00 | ₹1,118,303.00 |
| Indoco Remedies Limited | INDOCO | ₹275.10 | ₹25,377,397,290.00 | ₹25,198.00 |
Key Executives
Chief Executive Officer of Wholesale Lending-Piramal Enterprises Limited
Mr. Yesh Nadkarni
Gender: male
Year Born:
Managing Director of India Resurgence Asset Management Business Pvt. Ltd. (IndiaRF)
Mr. Shantanu Yeshwant Nalavadi
Gender: male
Year Born: 1971
Group President
Mr. Rupen Jhaveri
Gender: male
Year Born:
BR Head & Company Secretary
Mr. Bipin Singh
Gender: male
Year Born: 1968
Chief Financial Officer
Ms. Upma Goel
Gender: female
Year Born: 1971
Group General Counsel
Mr. Anand Vardhan
Gender: male
Year Born:
Executive Director
Mr. Anand Ajay Piramal
Gender: male
Year Born: 1984
Head of Investor Relations
Mr. Ravi Singh
Gender: male
Year Born:
Chief Human Resources Officer
Mr. Manjul Tilak
Gender: male
Year Born:
Executive Chairman
Mr. Ajay Gopikisan Piramal
Gender: male
Year Born: 1955
FAQs about Piramal Enterprises Limited
Who is the CEO of the company?
The CEO is Mr. Yesh Nadkarni.
What is the current market price of the stock?
The current price is ₹1,173.70.
What is the 52-week price range?
The range is ₹804.8-1275.
What is the market capitalization of the company?
The market capitalization is ₹26,605.20 crores.
What is the dividend yield?
The dividend yield is 0.85%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 50.89.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Piramal Enterprises Limited (ISIN: INE140A01024) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹26,605.20 crores and an average daily volume of 617,272 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹10.